Amorphous Solid Dispersion Tablets for Oral Exposure Stability

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing formulations of non-sedative anxiolytic APIs face challenges such as high melting point, poor in vitro solubility, low oral exposure, and significant food effect, leading to undesirable drug interactions and crystallization issues.

Innovation Solution

Development of a solid dispersion comprising a compound of formula (I) dispersed within a polymer matrix, using crystallization inhibitor polymers in a specific ratio, which is formulated into tablets through dry granulation and compression to maintain the amorphous form and minimize crystalline formation, thereby enhancing solubility and reducing food effect.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of manufacture

If the compound of formula (I) is formulated in conventional forms, then the formulation is simple to manufacture, but the compound exhibits poor in vitro solubility and low oral exposure

Engineering Contradiction:

Improveformulation simplicityVSAvoidoral exposure

Core Design Contradiction:

Ease of manufactureVSReliability

Solution Approach 1:

The patent changes the physical state of the compound from crystalline to amorphous by incorporating it into a solid dispersion matrix. This parameter change in molecular arrangement and physical form dramatically improves solubility and oral exposure while maintaining manufacturability through established solid dispersion techniques

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent creates a composite material system where the compound of formula (I) is dispersed within a polymer matrix. This composite structure combines the therapeutic compound with excipients in a solid dispersion formulation, achieving improved solubility and stability while remaining manufacturable using conventional pharmaceutical processing

Inventive Principle:

Principle #40Composite materials

2Ease of operation

If the compound is administered under conventional conditions, then the administration process is simple, but significant food effect is observed

Engineering Contradiction:

Improveadministration simplicityVSAvoidbioavailability consistency

Core Design Contradiction:

Ease of operationVSStability of the object's composition

Solution Approach 1:

The patent modifies the physical properties of the compound by converting it to an amorphous solid dispersion state. This parameter change in physical form reduces the compound's susceptibility to food effects and improves bioavailability consistency across different administration conditions while maintaining simple dosing regimens

Inventive Principle:

Principle #35Parameter changes

3Device complexity

If the compound is formulated without crystallization inhibitors, then the formulation composition is simpler, but crystalline forms form which have poor solubility

Engineering Contradiction:

Improveformulation compositionVSAvoidsolubility

Core Design Contradiction:

Device complexityVSReliability

Solution Approach 1:

The patent introduces a polymer matrix as an intermediary substance that disperses and stabilizes the compound of formula (I) in an amorphous state. This intermediary polymer prevents direct interaction between compound molecules that would lead to crystallization, thereby maintaining high solubility while adding only essential functional components to the formulation

Inventive Principle:

Principle #24Intermediary (Mediator)

4Productivity

If high loading of API is achieved, then the dosage efficiency is improved, but the risk of drug-drug interactions and crystallization increases

Engineering Contradiction:

Improvedosage efficiencyVSAvoidformulation stability

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The patent changes the physical state parameter of the API from crystalline to amorphous within the solid dispersion matrix. This parameter change allows high API loading concentrations without crystallization, maintaining formulation stability and preventing drug-drug interactions even at elevated dosages

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The polymer matrix serves as a protective intermediary that isolates high concentrations of API from each other, preventing crystallization and drug-drug interactions. This intermediary structure enables high loading efficiency while maintaining formulation stability through physical separation of API molecules

Inventive Principle:

Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The formulation achieves high loading of the API with improved in vivo solubility and minimizes adverse food effects, providing effective therapeutic plasma concentrations for up to 24 hours with reduced sedative side effects.

Implementation Method 1

dispersed within a polymer matrix formed by at least one pharmaceutically acceptable polymer

Methodology Applied

Scientific EffectAmorphous form stabilization:

Implementation Method 2

at least one pharmaceutically acceptable polymer is an at least one crystallisation inhibitor polymer

Methodology Applied

Scientific EffectCrystallization inhibition:

Data Source

PatentUS20260027057A1Therapeutic formulations and uses thereof

Publication Date: 2026.01.29 BONOMICS LTD

AI summary

This invention relates to formulations of compound (I) (BNC2IO), an allosteric modulator of the a7-nicotinic receptor with non-sedative anxiolytic effects; specifically, solid dispersions, methods of manufacture thereof, and therapeutic methods and uses in the treatment of diseases of the central nervous system thereof.